Rani Therapeutics Welcomes Kate McKinley as New Chief Business Officer

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company dedicated to revolutionizing the way we take our medication, proudly announces the appointment of Kate McKinley as its Chief Business Officer.

With her extensive experience in the biopharmaceutical industry, Ms. McKinley will be instrumental in the company’s pursuit of innovative dietary supplement solutions to provide improved patient outcomes. Rani looks forward to this fresh perspective and collaboration in furthering its mission of delivering drugs through its pioneering oral delivery method.

Rani is thrilled to welcome Kate to its executive team – a seasoned industry leader with expertise in corporate strategy, business development and commercialization. Kate will have a key role in furthering the growth and external innovation of the company and its RaniPill® platform technology, helping to unlock the full potential and value of the pipeline. Talat Imran, Chief Executive Officer of Rani, expresses his excitement for Kate’s arrival and the impact she will have in positioning the company for its next stage of growth.

For more than two decades, Ms. McKinley has climbed the ranks in the biopharmaceutical industry, leading teams to remarkable performance. In executive leadership, corporate strategy and business development, she has acquired an impressive array of skills for securing global partnerships, executing regulatory and commercial strategies in biologics, cell therapies and small molecules across multiple therapeutic areas, and leading in alliance management, commercial, supply chain and medical affairs. Her expertise is unrivalled in the industry.

Ms McKinley has had an array of leadership roles in the pharmaceutical, diagnostics, and health tech industries. She is currently the CEO and Board Member of Elevar Therapeutics, a company she joined in 2019 as their Chief Commercial Officer. Before joining Elevar, she was the Founder and CEO of Spark Outcomes, where she served as a corporate adviser for early-stage start-ups.

Her prior experience also includes commercial and business development across a range of companies, such as Dendreon, AbbVie and Abbott. Ms McKinley brings a wealth of industry knowledge and leadership experience to Rani.

Ms. McKinley is a proud summa cum laude graduate of The University of Tulsa’s Collins College of Business, where she achieved her MBA and Bachelor of Science in Business Administration with degrees in Marketing, Management and Psychology.

She currently serves on the Board of Directors of Maxwell Biosciences and chairs the Investment Committee. She was previously on the Board of Directors of Elevar Therapeutics and Hainan Pactil Advanced Therapeutics Company Ltd, cementing her reputation as a highly sought-after expert in the field.

I am delighted to join the talented executive team at Rani Therapeutics and to be part of this exciting journey. Rani’s RaniPill® capsule gives patients a unique and innovative drug delivery alternative to painful injections. I believe this groundbreaking technology has potential to greatly benefit a broad range of injectable therapeutics, which should prove incredibly attractive to both drug developers and patients alike.

About Rani Therapeutics

Rani Therapeutics is on a mission to revolutionize the world of biologics and drugs for oral dosing. Using their patented and proprietary RaniPill® capsule technology, they aim to replace the need for subcutaneous injection or intravenous infusion of these important medicines.

Rani has already conducted successful preclinical and clinical studies of the RaniPill® technology, demonstrating impressive safety, tolerability and bioavailability results. To learn more about this innovative approach to taking medications,

Forward-Looking Statements

Rani is making bold strides in the industry with the strengthening of its leadership team and ambitious partnering efforts. These developments, coupled with the advancement of its innovative RaniPill® platform technology, have made the company a sought-after destination for both patients and drug developers looking for a cutting-edge solution to their drug delivery needs.

However, there are risks and uncertainties that may hamper Rani’s growth, as described in its filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2022 and subsequent filings and reports. Despite this, Rani remains optimistic and is dedicated to continuing its mission of revolutionizing the drug delivery space.

Leave a Comment